Multi-center randomized open label phase II trial on three rituximab dosing schemes in immune thrombocytopenia patients

Haematologica. 2015 Mar;100(3):e90-2. doi: 10.3324/haematol.2014.110213. Epub 2014 Nov 25.
No abstract available

Keywords: early response; immune thrombocytopenia; open label phase II; rituximab; splenectomy delaying.

Publication types

  • Clinical Trial, Phase II
  • Letter
  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Antibodies, Monoclonal, Murine-Derived / therapeutic use*
  • Drug Administration Schedule
  • Drug Dosage Calculations
  • Female
  • Humans
  • Immunologic Factors / therapeutic use*
  • Male
  • Middle Aged
  • Purpura, Thrombocytopenic, Idiopathic / drug therapy*
  • Purpura, Thrombocytopenic, Idiopathic / immunology
  • Purpura, Thrombocytopenic, Idiopathic / mortality
  • Purpura, Thrombocytopenic, Idiopathic / pathology
  • Recurrence
  • Rituximab
  • Survival Analysis
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal, Murine-Derived
  • Immunologic Factors
  • Rituximab